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Background: Headache disorders and psychiatric disorders are both common, while evidence, mostly pertaining to
migraine, suggests they are comorbid more often than might be expected by chance. There are good reasons for
establishing whether they are: symptoms of comorbid illnesses may summate synergistically; comorbidities hinder
management, negatively influencing outcomes; high-level comorbidity indicates that, where one disease occurs,
the other should be looked for. The Eurolight project gathered population-based data on these disorders from 6624
participants.
Methods: Eurolight was a cross-sectional survey sampling from the adult populations (18–65 years) of 10 EU
countries. We used data from six. The questionnaire included headache-diagnostic questions based on ICHD-II, the
Headache-Attributed Lost Time (HALT) questionnaire, and HADS for depression and anxiety. We estimated odds
ratios (ORs) to show associations between migraine, tension-type headache (TTH) or probable medication-overuse
headache (pMOH) and depression or anxiety.
Results: pMOH was most strongly associated with both psychiatric disorders: for depression, ORs (vs no headache) were
5.5 [2.2–13.5] (p < 0.0001) in males, 5.5 [2.9–10.5] (p < 0.0001) in females; for anxiety, ORs were 10.4 [4.9–21.8] (p < 0.0001)
and 7.1 [4.5–11.2] (p < 0.0001). Migraine was also associated with both: for depression, ORs were 2.1 [1.3–3.4] (p = 0.002)
and 1.8 [1.1–3.1] (p= 0.030); for anxiety 4.2 [2.8–6.3] (p < 0.0001) and 2.4 [1.7–3.4] (p < 0.0001). TTH showed associations
only with anxiety: ORs 2.5 [1.7–3.7] (p < 0.0001) for males, 1.5 [1.1–2.1] (p = 0.021) for females. Participants with migraine
carried 19.1 % probability of comorbid anxiety, 6.9 % of depression and 5.1 % of both, higher than the representative
general-population sample (14.3, 5.6 and 3.8 %). Probabilities in those with MOH were 38.8, 16.9 and 14.4 %; in TTH, they
did not exceed those of the whole sample. Comorbid psychiatric disorder did not add to headache-attributed productive
time losses, but weak associations existed (R2 = 0.020–0.082) for all headache types between lost productive time and
probabilities of depression and, less so, anxiety.
Conclusion: In this large study we confirmed that depression and especially anxiety are comorbid more than by chance
with migraine, and showed the same is true, but more strongly, with MOH. Arguably, migraine patients and, more
certainly, MOH patients should be screened with HADS in pursuit of best outcomes.
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Headache disorders are very common. In the Global
Burden of Disease Study 2010 (GBD2010), tension-type
headache (TTH) and migraine were found to be the sec-
ond and third most prevalent disorders in the world [1].
Additionally, the group of disorders characterised by
headache recurring on ≥15 days/month affects 1.7–4 %
of the world’s adult population [2], many of them having
medication-overuse headache (MOH) [3]. Headache dis-
orders are also disabling: in GBD2013, they were
revealed as the third cause of disability worldwide [4, 5],
migraine and MOH being the substantial contributors.
Also in GBD2013, depression and anxiety, both common
psychiatric disorders, were ranked second and ninth
highest causes of disability worldwide [4].
Common disorders occur together (are comorbid) by
chance. Depression and anxiety are comorbid with each
other more than by chance [6]. In addition, several stud-
ies point to a higher probability (2 to 4 times) of psychi-
atric disorders among people with migraine [7–12]. Few
studies have specifically considered TTH, although
people with episodic TTH were found no more likely
than controls to experience anxiety or mood disorders
[13], while those among a Chinese elderly population
with chronic TTH were twice as likely to be suffering
from depression [14]. There is evidence associating psy-
chiatric morbidity with medication overuse [15], but no
data on psychiatric comorbidity with MOH in the gen-
eral population.
There are good reasons for wishing to establish
whether or not there are associations between the com-
mon headache disorders and the common psychiatric
disorders, all of them major contributors to public ill
health and the burden of disability. The symptoms of co-
morbid illnesses are expected to summate synergistically.
Comorbidities hinder management and negatively influ-
ence outcomes, more so when they are unrecognized.
Comorbidity occurring more than by chance indicates
that, where one disease occurs, the other should be
looked for. It also suggests causal relationships or com-
mon aetiological factors, which should be elucidated.
The Eurolight project was an initiative supported by
the European Commission Executive Agency for Health
and Consumers (EHAC), and a partnership activity
within the Global Campaign against Headache con-
ducted by Lifting The Burden (LTB), a UK-registered
non-governmental organization in official relations with
the World Health Organization. Eurolight gathered data
on these disorders from over 9000 variously-selected
adult participants in a questionnaire-based cross-
sectional survey conducted in 10 countries in Europe
[16]. The survey included demographic enquiry and
screened for headache, depression and anxiety, with
diagnostic questions for migraine, TTH and MOH. Weanalysed the data for evidence of associations between
depression and anxiety and headache type, by gender.
Methods
The methods of the Eurolight project have been
described in detail elsewhere [17], and are summarised
here.
Ethics
The National Ethics Committee of Luxembourg gave
overall approval of the protocol and provisions for data
protection. Further approvals were obtained from
national and/or local ethics committees wherever needed
as the methods for recruitment of participants differed
between countries. In every country, prospective partici-
pants received written information explaining the
project and its purpose.
Project design and sampling
Eurolight was a cross-sectional survey conducted from
November 2008 to August 2009. It used modified cluster
sampling in 10 countries which together represented
>60 % of the adult population (18–65 years) of the Euro-
pean Union: Austria, France, Germany, Ireland, Italy,
Lithuania, Luxembourg, Netherlands, Spain and United
Kingdom (UK). The sampling methods varied between
countries according to what was feasible, and are fully
described elsewhere [17]. They are summarised in
Table 1 for the six countries contributing to this analysis,
which are those with samples drawn from the general
population. In three other countries (Austria, France and
UK), sampling was to some extent patient-based
(although not headache patients), while additional
samples from Spain and the Netherlands, and the only
sample from Ireland, were recruited through patients’
organisations [17]. None of these was included in this
analysis because of the biases inherent in them.
Instruments
The survey used the same structured questionnaire in all
countries [18], a derivative of LTB’s HARDSHIP ques-
tionnaire developed for population-based surveys [19]. It
was translated into the local languages following LTB’s
translation protocol for lay documents [20]. It had mul-
tiple parts. Demographic questions were followed by
screening questions for headache and, in those screening
positively, by headache-diagnostic questions based on
ICHD-II [21]. The timeframe for enquiry was the pre-
ceding year. Participants identifying more than one
headache type were asked to report only on the one that
was most bothersome. Diagnoses were made by comput-
erized algorithm [19]. The algorithm first identified, and
separated, participants reporting headache on ≥15 days/
month, of whom additional questions enquired into
Table 1 Summary of data collection methods, and demographics of samples, in each country
Country Sampling and data collection method Questionnaires
distributed and returned
Gender n Age (years)
N/n (mean ± SD)
Germany Random urban (50 %) and rural (50 %) samples aged 18–65
years from general population listings supplied by local
municipal authority. Questionnaires distributed and returned
by post. No reminders sent.
3000/318 M 136 45.7 ± 13.4
F 182 43.8 ± 11.8
Italy Random urban (70 %) and rural (30 %) samples drawn
from general population using listings supplied by Azienda
Sanitaria Locale of Pavia, stratified with regard to gender,
age (in range 18–65 years) and education. Questionnaires
distributed and returned by post. No reminders sent.
3500/487 M 203 44.9 ± 12.9
F 284 42.4 ± 12.3
Lithuania Sample drawn from Kaunas city and Kaunas region using Residents’
Register Service, reflecting age (in range 18–65 years) and gender
composition of Lithuania and proportions living in rural (33 %)
or urban (67 %) areas. Data collection face-to-face, conducted by
medical students “cold-calling” door-to-door.
1137/573 M 237 39.8 ± 14.0
F 336 41.7 ± 13.7
Luxemburg Sample aged 18–65 years, stratified for age, gender, region
and nationality, drawn from general population via national
social security registry (IGSS). Questionnaires distributed and
returned by post. Reminders sent one month later to non-responders.
6498/1833 M 769 40.8 ± 12.8
F 1064 40.3 ± 12.6
Netherlands Survey conducted by market research company with access
to population sample of 200,000, representative with regard
to gender, age (in range 18–65 years), region and education.
Questionnaire distributed by internet, to be completed on-line.
Study stopped when >2000 received back.
unknown/2414 M 1214 43.7 ± 13.5
F 1200 41.6 ± 12.9
Spain Random sample of employees of companies operating in national
postal services in 10 areas of Spain, stratified to be representative
of general working population with regard to gender, age (in range
18–65 years) and education. Ten occupational health physicians delivered
and took return of questionnaires. One telephone reminder to non-responders.
1700/999 M 410 44.1 ± 11.9
F 589 41.7 ± 11.8
All unknown/6624 M 2969 42.9 ± 13.2
F 3655 41.4 ± 12.6
All 6624 42.1 ± 12.9
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when (a) duration was typically >4 h and (b) frequency
of acute medication use was ≥15 days/month and the
medication was simple analgesics only, or ≥10 days/
month when it was any other (compound analgesics,
opioids, triptans and/or ergots). A diagnosis of pMOH
trumped all other diagnoses. The remainder of this
group were diagnosed as “other headache on ≥15 days/
month”. To all others (with headache on <15 days/
month), the algorithm applied ICHD-II criteria for mi-
graine, TTH, probable migraine and probable TTH in
that order. In the analyses, migraine and probable
migraine were considered together, as were TTH and
probable TTH [22, 23].
To enquire into impact, the questionnaire imported
LTB’s Headache-Attributed Lost Time (HALT) Index as
a module. HALT captured lost productive time (days lost
completely, and days of <50 % productivity) from paid
and household work because of headache, and missed
social and leisure activities [24]. In the analysis of HALT
data, days of <50 % productivity were counted as and
added to wholly lost days, being counterbalanced bydays that were affected by headache but with productiv-
ity still >50 %, which were ignored. Lost paid workdays
and lost household workdays were summed separately,
and then totalled for lost productive time.
To assess anxiety and depression among participants,
the questionnaire imported, as a further module, the
Hospital Anxiety and Depression Scale (HADS) [25].
This screening instrument was preferred to more
specific instruments: firstly, it is easily applied in surveys
of this type; secondly – and more importantly – it
detects the subjective manifestations of anxiety and de-
pression rather than somatic symptoms of distress [25],
which, confoundingly, might include headache. HADS
consists of two subscales, HADS-Anxiety (HADS-A)
and HADS-Depression (HADS-D), each of seven items.
In response to each item, participants report their sub-
jective experience during the preceding week, rating it
0–3 (3 indicating maximum symptom severity). The
sum of each subscale has a potential range of 0–21. As
recommended in the original description [25], we took a
threshold of 11 on the respective subscale to indicate
caseness for anxiety or depression.
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Categorical variables are described in terms of frequency
(n) and proportions (%). Continuous variables are de-
scribed in terms of means ± standard deviations (SDs).
We calculated, as percentages with 95 % confidence
intervals (CIs), 1-year prevalences of migraine and TTH
and point prevalences of pMOH and other headache on
≥15 days/month in the participating sample, overall and
by gender. We calculated point prevalences of depres-
sion and anxiety, and of comorbid depression plus anx-
iety, in the participating sample overall, by gender and
by headache type. We performed logistic regressions,
stratified by gender, in order to explore associations
between all headache and headache types on the one
hand and depression and anxiety on the other, taking
the latter two as the dependent variables. We calculated
odds ratios (ORs) with 95 % CIs.
To establish whether depression or anxiety influenced
the impact of headache on lost productive time, we did
the following. For each headache type, we plotted
headache-attributed lost time (measured by HALT and
treated as continuous data) against HADS-D and
HADS-A scores (also continuous data), and performed
simple regression analyses, calculating R2 for the linear
trendlines. We also conducted this analysis in reverse,
with depression or anxiety rather than days lost as
dependent variables.
We performed analyses using Microsoft Excel:mac
2011 software version 14.5.7.
Results
Demographics
Eurolight collected 9269 correctly completed question-
naires from all 10 countries, but the population-based
sample from six countries included 6624 participants
(males 2969 [44.8 %]; females 3655 [55.2 %]; mean age
42.1 ± 12.9 years) (Table 1).
Prevalences
The prevalences of each headache type in this sample,
overall and by gender, are shown in Table 2. TTH
(39.4 %) was the most prevalent headache type, but only
a little more so than migraine (35.9 %). Both migraine
(1.6:1) and pMOH (2.8:1), but not TTH (0.9:1) were
more prevalent among females.Table 2 Prevalences of each headache type in the sample, overall a
Gender Prevalences (%) [95 % CI]
Migraine Tension-type headache Probabl
All (N = 6624) 35.9 [34.7–37.1] 39.4 [38.2–40.6] 3.0 [2.6–
Male (n = 2969) 26.9 [25.3–28.5] 41.6 [39.8–43.4] 1.5 [1.1–
Female (n = 3655) 43.1 [41.5–44.7] 37.7 [36.1–39.3] 4.2 [3.5–The prevalences of depression and anxiety, overall, by
gender and by headache type (the last indicating comor-
bidities between these disorders), are shown in Table 3.
Anxiety in the total sample was 2.5 times more prevalent
than depression. This ratio was reduced to 1.7:1 in the
subsample with no headache. Both disorders were more
prevalent among females: depression by a ratio of 1.2:1
(p = 0.0406), anxiety more so, by 1.8:1 (p < 0.0001; Fish-
er’s exact test).
Comorbidity
Depression and anxiety were highly comorbid with each
other in the total sample (3.8 % against an expectation
of 0.8 % from chance association alone).
In comparison with the total sample, depression and
anxiety were each comorbid more than by chance with
both migraine and pMOH but not with TTH or other
headache on ≥15 days/month. However, the lower part
of Table 3 indicates that anxiety was more prevalent in
those with any of the headache types than in those with
no headache. Depression was more prevalent in all but
other headache on ≥15 days/month, although in TTH
the excess was not significant. We confirmed these asso-
ciations by calculating ORs, which are presented in
Table 4. As predicted by the data in Table 3, the associa-
tions with pMOH were very strong. The analyses sug-
gested that all associations, except that between
depression and pMOH, were stronger in males than in
females.
To enquire into how comorbid depression or anxiety
influenced the impact of headache on lost productive
time, we plotted headache-attributed lost time (mea-
sured by HALT) against HADS-D and HADS-A scores.
We did this for migraine, TTH and pMOH, but found
no influence when treating days lost as the dependent
variable (R2 in the range 0.0005–0.01). However, with
the analyses reversed (depression and anxiety as dependent
variables), weak influences were detected in all cases: most
strongly between pMOH and depression (R2= 0.082) and
pMOH and anxiety (R2 = 0.059); next most strongly be-
tween TTH and depression (R2 = 0.036) and migraine and
depression (R2 = 0.031), and least strongly between TTH
and anxiety (R2 = 0.026) and migraine and anxiety (R2=
0.020). The relationships with migraine are shown in Fig. 1
to illustrate.nd by gender




Table 3 Prevalences of depression and anxiety in the sample, overall, by gender and by headache type
Prevalences (%) [95 % CI]
Depression Anxiety Depression + anxiety
All (N = 6624) 5.6 [5.0–6.2] 14.3 [13.7–15.1] 3.8 [3.3–4.3]
Gender
Male (n = 2969) 4.9 [4.1–5.7] 9.9 [8.8–11.0] 2.9 [2.3–3.5]
Female (n = 3655) 6.1 [5.3–6.9] 17.8 [16.6–19.0] 4.6 [3.9–5.3]
Headache type
No headache (n = 1271) 3.5 [2.5–4.5] 6.1 [4.8–7.4] 1.7 [1.0–2.4]
Migraine (n = 2375) 6.9 [5.9–7.9] 19.1 [17.5–20.7] 5.1 [4.2–6.0]
TTH (n = 2613) 4.5 [3.7–5.3] 12.1 [10.9–13.4] 3.0 [2.3–3.7]
pMOH (n = 201) 16.9 [11.7–22.1] 38.8 [32.1–45.5] 14.4 [9.5–19.3]
Other headache on ≥15 d/m (n = 164) 3.6 [0.8–6.4] 12.1 [7.1–17.1] 1.8 [0–3.8]
TTH tension-type headache, pMOH probable medication-overuse headache, d/m days/month
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The key findings were (1) a confirmation that anxiety in
particular, but also depression, are comorbid more than
is expected by chance with migraine, and (2) first clear
evidence of similar but stronger relationships with
pMOH. Anxiety but not depression was weakly comor-
bid with TTH.
Before we comment further on these findings, we need
to recall the limitations of the Eurolight study: the full
study was not entirely population-based, sampling
methods differed between countries [17], and participa-
tion rates were very low in some [16]. We were selective
here, analysing data only from samples drawn from the
general population, but even so we cannot argue that
the estimates of prevalence that we made use of were re-
liable. Eurolight was a study of headache impact rather
than prevalence [16], and this is no doubt reflected in
the reported migraine prevalence of 35.9 %, which is
much higher than the global and European means [1,
26] and only a little below that of TTH (39.4 %). The re-
ported prevalence of pMOH (3.0 %) was also on the high
side [3]. It was not, of course, a purpose of this study to
report prevalences of headache types, but we draw atten-
tion at the outset to this potential source of bias.
As for the prevalence estimates for psychiatric disor-
ders, we found that depression affected about one adult
in 20 (5.6 %), while anxiety was almost three times asTable 4 Associations between headache types and depression and
Headache type Odds ratios [95 % CI] vs no heada
Depression
Males p Female
Migraine 2.1 [1.3–3.4] 0.002 1.8 [1.1
Tension-type headache 1.1 [0.7–1.8] 0.597 1.3 [0.8
Probable medication-overuse headache 5.5 [2.2–13.5] <0.0001 5.5 [2.9
Other headache on ≥15 days/month 1.9 [0.7–5.7] 0.242 0.6 [0.1common (14.3 %). Both disorders were more prevalent
in females, but this gender association was much stron-
ger with anxiety. Recent reviews have estimated the glo-
bal prevalence of depression in the range 4.4–5.0 % [27]
and of anxiety in the range 4.8–10.9 % [28], with na-
tional studies generally finding these disorders to be
more prevalent in developed Western countries [29, 30].
Therefore our estimates were in keeping with expecta-
tions, while towards their upper limits. It should be
noted that HADS is a screening rather than diagnostic
instrument for these disorders [25], with a tendency to
underestimate prevalence of both [6]; we conclude,
therefore, that levels of psychopathology in the sample,
especially anxiety, were high. Depression and anxiety
were highly comorbid with each other, as is invariably
reported [6, 31].
We found, also, comorbidity at levels greater than
expected by chance between each psychiatric disorder
and each of migraine and pMOH. This, almost certainly,
is the explanation of the high levels of psychopathology
in our sample, especially since, on the psychiatric side,
the associations were stronger with anxiety. On the
headache side, the associations were strongest with
pMOH, but still strong with migraine. Only anxiety
showed an association with TTH, and this was weak.
Eurolight diagnosed only the most bothersome headache
type in participants reporting more than one [18, 22];anxiety, by gender
che as reference
Anxiety
s p Males p Females p
–3.1] 0.030 4.2 [2.8–6.3] <0.0001 2.4 [1.7–3.4] <0.0001
–2.3] 0.328 2.5 [1.7–3.7] <0.0001 1.5 [1.1–2.1] 0.021
–10.5] <0.0001 10.4 [4.9–21.8] <0.0001 7.1 [4.5–11.2] <0.0001
–2.9] 0.568 4.7 [2.1–9.7] 0.0001 1.3 [0.6–2.6] 0.474
Fig. 1 Illustrative plots with linear trendlines of HADS-D score (top) and HADS-A score (bottom) against headache-attributed lost time in participants
with migraine
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scribe the former as more bothersome and not report
the latter. While the prevalence of TTH might as a re-
sult be underestimated [22], this could not have masked
an association between depression and TTH uncompli-
cated by migraine.
Multiple studies have earlier found increased preva-
lences of depression and anxiety in people with migraine
relative to those without headache [12, 32–34]. Migraine
and anxiety are clearly comorbid, and several studies have
demonstrated, as we did, that this association is stronger
than that between migraine and depression [11, 35, 36].
However, relatively few population-based data exist on
psychiatric comorbidity with TTH. Merikangas found no
increased comorbidity between either depression or
anxiety and TTH in a Swiss study [7]; we were almost in
agreement with her. On the other hand, the very large
Norwegian HUNT study found that both migraine andnon-migrainous headache (80 % of the latter being TTH)
were comorbid with anxiety and depression (36).
For all headache types, these relationships became
more pronounced with increasing headache frequency.
The spectrum of highly-frequent headache (occurring
on ≥15 days/month) includes chronic migraine, chronic
TTH and MOH. Eurolight did not attempt to diagnose
the first two, which cannot be done reliably in such
surveys [22], but we found strong associations with
pMOH: ORs of 5.5 for depression and 7–10 (greater in
males) for anxiety. Until now, no population-based stud-
ies have specifically assessed psychiatric comorbidity
with MOH, although in clinical samples MOH patients
frequently exhibit depression and anxiety [37]. It has
also been shown that depression and anxiety are risk fac-
tors for developing MOH in migraineurs [38], so comor-
bidity is not surprising. Nevertheless, this study is the
first to show it.
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gender-relationship, being stronger in males. Although
individual differences were not significant, the consistency
is striking. Victor et al., in a US study, observed that males
with migraine were more likely than females with
migraine to report anxiety or depressive symptoms com-
pared with the same gender without headache [33]. How-
ever, a much earlier US study had found no gender
difference in comorbidity between migraine and major
depression or anxiety disorders [39]. If such a difference
should exist, we would presume that the socio-
environmental and/or genetic factors explaining these co-
morbidities do not play exactly the same roles in males as
in females.
On a clinical level, the importance of these associa-
tions is in how they might influence management. The
key question is: should a physician treating a patient
complaining of headache screen for comorbid psychi-
atric disorder? The data in the lower part of Table 3 in-
dicate the probabilities of comorbid depression or
anxiety by headache type, and are likely to be applicable
to patients typically seen in primary care rather than
those who have found their way to specialised clinics. A
patient with migraine has a 19 % probability of comorbid
anxiety, almost 7 % of depression and 5 % of both. These
are certainly higher, but not dramatically so, than the
14.3, 5.6 and 3.8 % in the entire sample representative of
the general population. On the other hand, comorbid
psychiatric disorder, when present, adds to overall mor-
bidity and, if not identified and itself treated, leads to
unsuccessful headache management, or at least a poorer
outcome. This suggests that, even in primary care where
time is at a premium, there is a case for screening mi-
graine patients with HADS. Against this it may be ar-
gued that, if anxiety – the more common comorbid
disorder by a large margin – is actually secondary to the
worrying headache symptoms that have brought the pa-
tient into a consultation, then treating the headache is
the priority and perhaps all that is necessary. We have
recently shown that interictal anxiety is an important
component of the burden of migraine [40]. In a patient
with MOH, the probability of comorbid anxiety is al-
most 39 %, of depression 17 % and of both 14 %, which
make the case for screening with HADS considerably
more compelling. In TTH, the probabilities do not ex-
ceed those of the whole sample. In all cases, probabilities
are higher in females than males, but this reflects the
underlying prevalences of these disorders.
On a public-health level, our interest was more in how
the effects of these comorbid disorders might summate.
We assumed that a psychiatric disorder, when present,
would add to overall morbidity and that this would be
evident in the HALT analysis. We found, instead, that
comorbid anxiety or depression did not add significantlyto lost productive time attributable to headache. But
there was a weak association – with all headache types,
but most strongly pMOH – between lost productive
time and the probability of depression or, less so, anx-
iety. We can speculate that this indicated cause: that co-
morbid anxiety and depression were at least in part the
consequences of increasing lost productive time (or of
the symptoms causing it), rather than due to underlying
biological susceptibility. We have no further evidence in
support of this idea.
While the Eurolight study had a number of methodo-
logical limitations, mentioned earlier, it also had several
strengths. It was a European community-wide survey,
sampling from ten countries [17], of which we took six
(from west, north, east, central and south Europe) that
provided population-based data. It used a validated
questionnaire (HARDSHIP) diagnosing headache types
by applying modified ICHD-II criteria algorithmically
[19] and a widely accepted screening instrument
(HADS) for psychiatric disorders [25]. It is, for the time
being, the only source of population-based gender-
specific data on psychiatric comorbidity with TTH and
MOH.
Conclusion
In this large cross-sectional European study, we confirmed
that depression and especially anxiety are comorbid more
than is expected by chance with migraine. We found the
same, but more strongly, with pMOH, and that anxiety
but not depression is weakly comorbid with TTH. There
is an arguable case for screening migraine patients with
HADS, and a stronger case for MOH patients, in order to
achieve best outcomes. Comorbid anxiety or depression
did not add to lost productive time, but weak associations
existed in all headache types between lost productive time
and the probability of depression or, less so, anxiety.
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